Staff Reports
Federal health data are painting a mixed picture: provisional counts show overall overdose deaths falling after a deadly run of years, yet poison centers are reporting a sudden and sharp rise in kratom exposures. That pairing deserves attention — not panic, not blind celebration — but clear, commonsense action from Washington and the states.
Overdose deaths fall while kratom reports spike — two trends, one story?
The Centers for Disease Control and Prevention’s provisional numbers show a notable drop in total overdose deaths in 2025, including fewer opioid-involved fatalities. At the same time, a CDC MMWR analysis using poison-center data and a University of Virginia review found kratom-related calls surged, with more than 3,400 exposures reported to poison centers in 2025 alone. Dr. Christopher Holstege of UVA’s Blue Ridge Poison Center warns that kratom exposures, hospitalizations and even deaths tied to kratom products climbed sharply, and that some newer products contain highly potent compounds like 7‑hydroxymitragynine.
Correlation isn’t causation — don’t be fooled by neat headlines
Here’s the critical point the headlines skip: the drop in overdose deaths and the kratom surge are measured by two different systems. One tracks deaths; the other tracks poison‑center calls. The MMWR also shows most kratom-associated deaths involved other drugs — polysubstance use is common — and poison-center reports capture only known exposures. In plain language: the data show two worrying trends at once, but they don’t prove Americans are trading fentanyl for kratom like it’s a new backup plan. That claim would be tempting clickbait, not responsible reporting.
Why kratom is suddenly a public-health headache
Kratom is legal in most states and sold in many forms: powders, gummies, drinks and concentrated extracts. The danger is twofold. First, some products are stronger than the traditional botanical and contain higher levels of 7‑hydroxymitragynine, an opioid-like compound the FDA has flagged as an emerging threat. Second, these products are popping up in convenience stores, vape shops and near colleges — sometimes marketed to young people as a caffeine or alcohol alternative. Call it a regulatory blind spot: while law-enforcement efforts under President Trump have squeezed the fentanyl pipeline, unregulated products like high-potency kratom have spread quietly through retail channels.
What conservative common sense should demand
We can applaud tougher enforcement on fentanyl while pushing common-sense limits on dangerous unregulated products. The FDA should move faster to classify and restrict concentrated 7‑hydroxymitragynine formulations and use import controls and seizures more aggressively. States should bar sales to minors, require clear labeling and test-product safety, and local law enforcement should crack down on illicit distributors. At the same time, fund addiction treatment and public education so worried parents don’t have to field this threat alone — because right now convenience stores are too often acting like public-health mystery shops selling unknown-strength “gummies.”
The data offer a second chance to get drug policy right: keep pressing law enforcement on fentanyl, but don’t let regulatory gaps create a new crisis in plain sight. Kratom’s rise is a problem we can fix with smart rules, better surveillance and a dose of common sense — and yes, a little tough love for shops that think selling risky extracts to teenagers is a good business plan.
